Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Monaco

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
British Journal of Haematology|November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trialGiulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Haematologica|May 12, 2018
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>Sergio Storti, Michele Spina, Emanuela Anna Pesce, et al.
Bone Marrow Transplantation|January 11, 2022
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMTLaure Vincent, Luuk Gras, Patrice Ceballos, et al.
The Oncologist|April 4, 2019
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical PracticeAlessandro Broccoli, Beatrice Casadei, Annalisa Chiappella, et al.
Blood Cancer Journal|May 20, 2020
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II studyRoberto Mina, Angelo Belotti, Maria Teresa Petrucci, et al.
Blood Cancer Journal|June 7, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsMattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Blood Cancer Journal|December 8, 2021
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trialRoberto Mina, Antonietta Pia Falcone, Sara Bringhen, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
British Journal of Haematology|November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trialGiulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Haematologica|May 12, 2018
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>Sergio Storti, Michele Spina, Emanuela Anna Pesce, et al.
Bone Marrow Transplantation|January 11, 2022
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMTLaure Vincent, Luuk Gras, Patrice Ceballos, et al.
The Oncologist|April 4, 2019
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical PracticeAlessandro Broccoli, Beatrice Casadei, Annalisa Chiappella, et al.
Blood Cancer Journal|May 20, 2020
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II studyRoberto Mina, Angelo Belotti, Maria Teresa Petrucci, et al.
Blood Cancer Journal|June 7, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsMattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Blood Cancer Journal|December 8, 2021
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trialRoberto Mina, Antonietta Pia Falcone, Sara Bringhen, et al.
Pageof 3